A5065524115- Cancer Cells and Metastasis
- Brain Metastases and Treatment
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Advanced Biosensing Techniques and Applications
- T-cell and B-cell Immunology
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Long-Term Effects of COVID-19
- World Systems and Global Transformations
- Cell Image Analysis Techniques
- Multiple Myeloma Research and Treatments
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Globalization and political ideologies
Dana-Farber Cancer Institute
2024
Amyloidosis Foundation
2023-2024
Boston University
2023-2024
Stanford University
2017-2022
A central feature of the SARS-CoV-2 pandemic is that some individuals become severely ill or die, whereas others have only a mild disease course are asymptomatic. Here we report development an improved multimeric αβ T cell staining reagent platform, with each maxi-ferritin "spheromer" displaying 12 peptide-MHC complexes. Spheromers stain specific cells more efficiently than tetramers and capture broader portion sequence repertoire for given peptide-MHC. Analyzing response in unexposed...
Coronary artery disease is an incurable, life-threatening that was once considered primarily a disorder of lipid deposition. now also characterized by chronic inflammation' notable for the buildup atherosclerotic plaques containing immune cells in various states activation and differentiation. Understanding how these contribute to progression may lead development novel therapeutic strategies.
Abstract Purpose: Eribulin modulates the tumor-immune microenvironment via cGAS-STING signaling in preclinical models. This non-randomized phase II trial evaluated combination of eribulin and pembrolizumab patients with soft-tissue sarcomas (STS). Patients Methods: enrolled one three cohorts: leiomyosarcoma (LMS), liposarcomas (LPS), or other STS that may benefit from PD-1 inhibitors, including undifferentiated pleomorphic sarcoma (UPS). was administered at 1.4 mg/m2 i.v. (days 1 8)...
For more than five years, high-dimensional mass cytometry has been employed to study immunology. However, these studies have typically performed in one laboratory on or few instruments. We present the results of a six-center using healthy control human peripheral blood mononuclear cells (PBMCs) and commercially available reagents test intra-site inter-site variation cytometers operators. used prestained controls generated by primary center as reference compare against samples stained at each...
Abstract Background Vascular endothelial growth factor is associated with reduced immune response and impaired anti-tumor activity. Combining antiangiogenic agents checkpoint inhibition can overcome this suppression enhance treatment efficacy. Methods This study investigated the combination of ziv-aflibercept anti-angiogenic therapy pembrolizumab in patients advanced melanoma resistant to anti-PD-1 treatment. Baseline on-treatment plasma PBMC samples were analyzed by multiplex protein assay...
Introduction Monoclonal antibody light chain proteins secreted by clonal plasma cells cause tissue damage due to amyloid deposition and other mechanisms. The unique protein sequence associated with each case contributes the diversity of clinical features observed in patients. Extensive work has characterized many chains multiple myeloma, amyloidosis disorders, which we have collected publicly accessible database, AL-Base. However, makes it difficult determine contribution specific amino acid...
<div>AbstractPurpose:<p>Eribulin modulates the tumor-immune microenvironment via cGAS-STING signaling in preclinical models. This non-randomized phase II trial evaluated combination of eribulin and pembrolizumab patients with soft-tissue sarcomas (STS).</p>Patients Methods:<p>Patients enrolled one three cohorts: leiomyosarcoma (LMS), liposarcomas (LPS), or other STS that may benefit from PD-1 inhibitors, including undifferentiated pleomorphic sarcoma (UPS). Eribulin...
<p>Supplementary Figure 1. Change in sum of longest tumor diameters across response assessments liposarcoma and UPS/Other cohorts.</p>
Each monoclonal antibody light chain associated with AL amyloidosis has a unique sequence. Defining how these sequences lead to amyloid deposition could facilitate faster diagnosis and new treatments.
Background Each monoclonal antibody light chain associated with AL amyloidosis has a unique sequence. Defining how these sequences drive amyloid deposition could facilitate faster diagnosis and lead to new treatments.
<div>AbstractPurpose:<p>Eribulin modulates the tumor-immune microenvironment via cGAS-STING signaling in preclinical models. This non-randomized phase II trial evaluated combination of eribulin and pembrolizumab patients with soft-tissue sarcomas (STS).</p>Patients Methods:<p>Patients enrolled one three cohorts: leiomyosarcoma (LMS), liposarcomas (LPS), or other STS that may benefit from PD-1 inhibitors, including undifferentiated pleomorphic sarcoma (UPS). Eribulin...
<p>Supplementary Figure 1. Change in sum of longest tumor diameters across response assessments liposarcoma and UPS/Other cohorts.</p>
<p>Supplementary Material. Study Protocol.</p>
<p>Supplementary Figure 2. Serum cytokine levels.</p>
<p>Supplementary Material. Study Protocol.</p>
<p>Supplementary Figure 2. Serum cytokine levels.</p>